Glossary of Hostile Takeover Terms with Discussion

Quote
  • Shoham   Apr 05, 2017 at 11:55: PM
Hey everyone:

Another milestone in the slow-motion collapse of VRX: Today, for the first time (since we got interested, at least), VRX dropped into single digits territory -- closing at $9.50. Down about 15% this week alone (and the week is still young). The media is giving different stories as to the reason: That they are not getting the prices they were hoping for when auctioning off their assets, that the new CEO (Papa) is getting a very generous compensation package, and that Michael Pearson is suing Valeant for not honoring his exit package.

With regards to the first: You could've read about this here 2 years ago. The business is simply not worth as much as they paid for it (with borrowed money); and finding out that no one else would pay so much shouldn't be a surprise. If you outbid everyone else to acquire an asset, then strip it down and run it to the ground, don't expect others to pay even more to take it off your hands.

As for the second: I'm no fan of Papa, not by a long stretch, but lets be real, once Pearson was pushed out, getting any CEO with realistic credentials to try and salvage the situation was going to require more than just "we all need to make sacrifices" type of compensation package. And, besides, his big numbers are all just in the event he somehow takes the stock back to the stratosphere -- ain't gonna happen, but if it does, he would surely deserve the big payday. For now, he was forced to invest $5M of his own money as an employment condition, and his $1M annual salary doesn't even begin to cover how much he's already lost of that $5M.

And as for the Pearson lawsuit, it reminds me of an old dark humor Joke:
Q: What is the definition of Chutzpah?
A: A man convicted of murdering his parents pleads the sentencing judge for mercy because he is an orphan.

Hope everyone is doing well!

Dan
 












  • Shoham   Apr 20, 2017 at 05:28: PM
anonymous said:
Dan - would love to collect your thoughts....

https://seekingalpha.com/article/4063057-allergan-triumph-financial-engineering-reality
Click to expand...

Thanks.

I didn't read the whole article, but I think I got the gist.

I am in total agreement with the author (and SEC) that these non-GAAP measure, and particularly "cash EPS", are more deceptive than informative. I also share his wariness of managements that seem to ask investors to pay no mind to GAAP earnings, and instead focus on cash EPS. As to his calculation of the corresponding stock price, as everyone here already knows, I don't do that. He isn't saying anything that the market doesn't already know, and the market is currently pricing the stock as it does (rightly or wrongly).

In non-accountant-speak: There is a well established methodology, developed over the past 500 years, of figuring out how much profit a company is making (and other financial reports). It is summarized as "Generally Accepted Accounting Principals" (GAAP). GAAP carefully takes account of expenses and revenues even when they do not have immediate cash impact. For example, if a company spends $X on developing a drug (or a software, or buy a machine, or a building; or, really, anything that will be used in the future); under GAAP, the profits made by the drug each year is reduced by some portion of $X to account for the fact that developing the drug wasn't free. Companies are required to report their financial statements in compliance with GAAP; but there is nothing that prevents them from adding non-GAAP metrics that they feel will be relevant to their investors -- so long as those metrics are defined, truthfully reported, and not deceptive. "Cash EPS" is one such popular non-GAAP metric (so popular, that sometimes the terms "non-GAAP" and "Cash EPS" are used interchangeably). It is intended as a counterpart to GAAP EPS (Earning Per Share -- Total profits divided by total number of shares). Because it is not part of GAAP, there is no definitive definition; and companies sometimes have different computations -- and they sometimes change the computation from year to year. The basic thesis of "Cash EPS" is the removal of all expense items that did not involve cash expenditure during the reporting period (this is a close concept to EBITDA -- Earning Before Interest, Taxes, Depreciation, and Amortization -- but there are some differences). Because a lot of "non-cash" expenses are taken out, it makes the profit seem (a lot) larger. It also creates an image of the company as a machine that just creates money at a furious and sustained rate.

But, it isn't sustainable. Drugs, or software, or machines, or buildings, (etc.) will need to be maintained, upgraded, serviced, and eventually replaced. They are not immortal revenue machines. The GAAP rules capture this mortality very methodically. Dispensing with those rules may look great, temporarily; but misses the bigger picture.

So, bottom line: Pay attention to the GAAP numbers, and have healthy skepticism of all non-GAAP -- especially "cash EPS" -- metrics.

Dan.
 


















  • Shoham   Aug 05, 2017 at 04:23: AM
Oh, that's easy. It's all about Teva.

Remember, when the Teva deal was working it's way, I was concerned that Teva overpaid and they would bail before closing. Well, they didn't bail (they should have, but lucky for us they didn't) and, indeed, overpaid. So what happened? The super-optimistic projections that were needed for Teva to justify the lofty price they paid us for the generic portfolio, surprise, surprise, didn't pan out. So Teva missed their numbers, big time. They dropped over 30% this week.

So why is this a problem for us?
While we got most of the $40B for the generic portfolio we sold to Teva in cash, some of it (my memory says about 10%, but I'm too lazy to go check) came in Teva stocks. Those stocks are worth a lot less this week than last week. (We promised not to sell those stock for something like one year, and we are still just within this restricted period; bummer). That drop alone reduce our market cap by a good chunk. Additionally, the big Teva miss is weighing on all drug makers, particularly those with big generic portfolios, because it is showing that its getting harder to make good profits in generics.

But, hey, look at the bright side: We got a lot more for the generic portfolio we sold to Teva than we now know it was worth. Even if the portion we got in Teva stocks is taking a beating, we took most of the cash off the table before the beating started. So, really, we are still way ahead of where we would have been without this deal.

Dan.
 












I've read every post on this thread since June 13, 2014. So for the past 3+ years THIS thread has been the most helpful/enlightening/educational post of ANY company and ANY thread. Why? One word. DAN!!!
I therefore nominate "DAN" to have his very own board! I would read it every day. Have a great one everybody!! :)
 






anonymous said:
I've read every post on this thread since June 13, 2014. So for the past 3+ years THIS thread has been the most helpful/enlightening/educational post of ANY company and ANY thread. Why? One word. DAN!!!
I therefore nominate "DAN" to have his very own board! I would read it every day. Have a great one everybody!! :)
Click to expand...
Dan any new thoughts?
 


















Hey Dan- Have you figured out yet that Allergan is a Roll-Up?

Clue-in. Allergan is simply a company that grows via acquisition, accounting tricks, and shady deals with Indian Tribes.

Overpaid for Teva. Overpaid for Kybella. Overpaid for Zeltiq. Overpaid for Lifecell, and bought a pastry bag (Keller) for 60 Million. Genius!

Kybella is a bust. Zeltiq was topped-out when they bought them. Lifecell already has 90% market share and now recalls.

Who do we buy next so we can act like we are growing?
 


















anonymous said:
Hey Dan- Have you figured out yet that Allergan is a Roll-Up?

Clue-in. Allergan is simply a company that grows via acquisition, accounting tricks, and shady deals with Indian Tribes.

Overpaid for Teva. Overpaid for Kybella. Overpaid for Zeltiq. Overpaid for Lifecell, and bought a pastry bag (Keller) for 60 Million. Genius!

Kybella is a bust. Zeltiq was topped-out when they bought them. Lifecell already has 90% market share and now recalls.

Who do we buy next so we can act like we are growing?
Click to expand...
 






anonymous said:
Hey Dan- Have you figured out yet that Allergan is a Roll-Up?

Clue-in. Allergan is simply a company that grows via acquisition, accounting tricks, and shady deals with Indian Tribes.

Overpaid for Teva. Overpaid for Kybella. Overpaid for Zeltiq. Overpaid for Lifecell, and bought a pastry bag (Keller) for 60 Million. Genius!

Kybella is a bust. Zeltiq was topped-out when they bought them. Lifecell already has 90% market share and now recalls.

Who do we buy next so we can act like we are growing?
Click to expand...
Why not Ironwood?
 






anonymous said:
Hey Dan- Have you figured out yet that Allergan is a Roll-Up?

Clue-in. Allergan is simply a company that grows via acquisition, accounting tricks, and shady deals with Indian Tribes.

Overpaid for Teva. Overpaid for Kybella. Overpaid for Zeltiq. Overpaid for Lifecell, and bought a pastry bag (Keller) for 60 Million. Genius!

Kybella is a bust. Zeltiq was topped-out when they bought them. Lifecell already has 90% market share and now recalls.

Who do we buy next so we can act like we are growing?
Click to expand...
 












anonymous said:
Dan - some words of wisdom please!!

Thoughts on current stock price, longevity of current executive management team, Restasis fiasco, future of Allergan
Click to expand...
Honestly you have to stop asking people for wisdom on this company—no one can predict the actions of management...and the obvious remains that this company is in turmoil. Where it goes from here is anyone’s guess. Saunders has proven to be unfit for this company but the next steps are all up in the air as long as he is on the board of directors. Whether the company remains anemic until he leaves years from now or months can’t be predicted.
 












Top Bottom
Back
Quote